BIO Welcomes Advances in Stem Cell Research

WASHINGTON--(BUSINESS WIRE)--BIO President and CEO Jim Greenwood issued the following statement regarding the news that researchers at the Harvard Stem Cell Institute created 20 disease-specific stem cell lines thru the new induced pluripotent stem cell (iPS) technique:

“The creation of stem cells lines carrying the genes or genetic components of ten diseases is a great step forward in the quest to understand, treat and eventually cure disease. We commend the Institute for their research and for making these stem cell lines available to researchers around the world to study.

“As the researchers have noted, while these stem cell lines were created thru iPS, we should not abandon other promising areas of research such as embryonic stem cell research. We must do all we can to accelerate research and explore all avenues of therapeutic possibilities to their fullest to determine which areas can present treatment options fastest.

“BIO will continue to support and advocate for increased funding for all promising areas of therapeutic research.”

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. www.bio.org

Upcoming BIO Events

Biotechnology Industry Organization (BIO)
Stephanie Fischer, 202-312-9263
sfischer@bio.org
www.bio.org